SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001640334-21-001335
Filing Date
2021-06-11
Accepted
2021-06-11 15:04:25
Documents
5
Period of Report
2020-12-31

Document Format Files

Seq Description Document Type Size
1 20-F/A nymox_20f.htm 20-F/A 20249
2 CERTIFICATION nymox_12a.htm EX-12.A 9623
3 CERTIFICATION nymox_12b.htm EX-12.B 8809
4 CERTIFICATION nymox_13a.htm EX-13.A 3242
5 CERTIFICATION nymox_13b.htm EX-13.B 3208
  Complete submission text file 0001640334-21-001335.txt   46182
Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2
Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669
NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 20-F/A | Act: 34 | File No.: 001-12033 | Film No.: 211010926
SIC: 2835 In Vitro & In Vivo Diagnostic Substances